Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2010
12/21/2010US7855298 (1S,5R)-1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-3-azabicyclo[3.1.0]hexane; or(1S,5R)-3-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)oxy]propyl}-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane; schizophrenia
12/21/2010US7855297 Amide derivatives and medicinal use thereof
12/21/2010US7855295 Tetrahydrocarboline compounds as anticancer agents
12/21/2010US7855294 (6R,8S)-6-(spiro[isobenzofuran-1-(3H), 4'-piperidin]-1'-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-ol), exhibiting an antagonism to binding of nociceptin to opioid receptor-like-1 receptors, useful as medicines for diseases associated with pain and appetite control or memory and learning
12/21/2010US7855291 Process for the preparation of substituted phenylalanines
12/21/2010US7855289 Sirtuin modulating compounds
12/21/2010US7855288 For treatment of cytokine-associated conditions
12/21/2010US7855278 antibodies which induces the death of a cell that expresses Stra6 polypeptide; used to prevent or slow down (lessen) the development, growth, or spread of tumor characterized by the overexpression of a PRO10282 polypeptide; chemotherapy
12/21/2010US7855233 Monorasagiline citrate; salt formation; monoamine oxidase inhibitors; side effects reduction; carriers; tablets; transdermal patches; Parkinson's disease; brain disorders; nervous system disorders; neurodegenerative disease; multiple sclerosis
12/21/2010US7855232 Organoselenium compound for cancer chemoprevention
12/21/2010US7855230 FDA Orange book listed patent for fesoterodine fumarate; urinary incontinence; isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester is fesoteridine
12/21/2010US7855229 Treating wasting disorders with selective androgen receptor modulators
12/21/2010US7855228 S-benzylisothiourea derivatives such as S-(3,4-Dichlorobenzyl)isothiourea, used for treating bacterial infections
12/21/2010US7855227 2-[[2-[4-(3-Fluoro-benzyloxy)-3-methoxy-phenyl]-ethyl]-isobutylamino]-N-methyl-acetamide, useful in preventing neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urogenital and gastrointestinal disorders
12/21/2010US7855226 Treatment of inflammatory bowel disease
12/21/2010US7855225 17βHSD type 5 inhibitor
12/21/2010US7855224 treating diabetes, Alzheimer's disease, Parkinson's disease, attention deficit disorder, schizophrenia, epilepsy, narcolepsy, pain and headaches, comprising administering 5-Methyl-2-methoxymethyl-1-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-indole
12/21/2010US7855223 methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof
12/21/2010US7855222 indazole derivatives such as 5-[4-(1-amino-1-methylethyl)phenyl]-1H-indazole, used for the treatment of vision defects
12/21/2010US7855221 Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
12/21/2010US7855220 sodium channel and calcium channel inhibitors, such as 2-Indol-1-yl-N-[5-(thiazol-2-ylsulfamoyl)-naphthalen-1-yl]-propionamide, used as analgesics or for the treatment of neurodegenerative disorders, anxiety, depression, arrhythmia, ataxia, multiple sclerosis, irritable bowel syndrome or incontinence
12/21/2010US7855219 2-Amino-4-(1,3-benzodioxol-5-yl)-6-benzyloxy-3,5-pyridinedicarbonitrile, acting as adenosine-receptor-selective ligands, for the prophylaxis and/or treatment of cardiovascular disorders
12/21/2010US7855218 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels
12/21/2010US7855217 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
12/21/2010US7855216 e.g. 3-(4-Bromo-2-fluoro-phenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid ethyl ester; MEK kinase (Mitogen-Activated protein kinase kinase) inhibitor; anticarcinogenic, antiinflammatory agent; rheumatoid arthritis
12/21/2010US7855215 such as 6-(6-Amino-pyrimidin-4-yloxy)-3,4-dihydro-2H-quinoline-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, used for the treatment of leukemia
12/21/2010US7855214 Autoimmune, inflammatory, proliferative, or hyperproliferative disease or an immunologically-mediated disease; inhibitors of the Tec family of non-receptor tyrosine kinases; compounds are quinazolino[3,2-a]quinazolin-12-ones
12/21/2010US7855213 e.g. 3-(3'-Methoxy-biphenyl-3-yl)-3-(4-methoxy-phenyl)-3H-isoindol-1-ylamine trifluoroacetate; beta -secretase, pepsin-like aspartic proteinase inhibitor; neurodegenerative diseases, cognitive impairment, Alzheimer's, Parkinson's Diseases, Down syndrome, and dementia
12/21/2010US7855212 Pyridinyl acetonitriles
12/21/2010US7855211 such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases
12/21/2010US7855210 Hydroxyiminopiperazine compounds, used as vanilloid receptor antagonists; analgesics
12/21/2010US7855209 2-aminothiophene derivatives; {2-Amino-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic for chronic neuropathic pain, cardiac disarrhythmias, angina; neurological disease or injury, sleep disorder, epilepsy, antidepressants
12/21/2010US7855208 cholinergic ligands such as (9-Methyl-3,9-diaza-bicyclo[3.3.1]non-3-yl)-[5-(4-nitro-phenyl)-furan-2-yl]-methanone, useful for the treatment of nervous system disorders, disorders related to smooth muscle contraction, endocrine diseases, neurodegenerative diseases, inflammation, pain, and drug abuse
12/21/2010US7855207 such as 6-[(1R)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-piperidin-1-ylpropyl]-3-ethyl-1H-quinolin-2-one, used for treating cancer and/or preventing cellular, tissue and/or organ damage resulting from cell damage or death due to, for example, necrosis or apoptosis
12/21/2010US7855206 antidiabetic agents such as (1S,2R,5S)-5-(2-Methyl-6,8-dihydro-7H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidin-7-yl)-2-(2,4,5-trifluorophenyl)cyclohexanamine bis-hydrochloride salt, used for treating non-insulin dependent diabetes
12/21/2010US7855205 Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
12/21/2010US7855204 cell surface tyrosine receptor kinases; non-small cell lung cancer; (3-chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine
12/21/2010US7855203 Indazolyl-substituted pyrroline compounds as kinase inhibitors
12/21/2010US7855202 useful in the treatment respiratory system disorders, allergic diseases, inflammation, reperfusion injury, ischemia, atherosclerosis, hypertension, retinopathy, diabetes, gastrointestinal disorders and/or autoimmune diseases
12/21/2010US7855201 Morpholine carboxamide prokineticin receptor antagonists
12/21/2010US7855200 Analogues of Oroxylin-A, Chrysin and Baicalein as antiulcer agents and mucoprotective agents from a new source new source Oroxylum indicum dried stem bark; flavanoids; gastrointestinal disorders; peptic ulcers; side effect reduction
12/21/2010US7855199 antitumor agents such as 2-(2-difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine, used for inhibiting the growth of a human colon cancer cell, a human lung cancer cell, a human breast cancer cell or a human prostate cancer cell
12/21/2010US7855198 Benzamide derivative or salt thereof
12/21/2010US7855197 Administering Diamino-substituted phenothiazinium compound; antimicrobial photosensitisers effective against Gram negative bacteria, Gram positive bacteria; photodynamic therapy
12/21/2010US7855196 Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
12/21/2010US7855195 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
12/21/2010US7855194 Pyrimidine, quinazoline, pteridine and triazine derivatives
12/21/2010US7855193 1-(4-(5-Phenylbenzofuran-2-yl)benzyl)azetidine-3-carboxylic acids; anticarcinogenic, antiinflammatory, antiarthritic, antidiabetic agents; transplant rejection, autoimmune diseases, lupus, multiple sclerosis, psoriasis, inflammatory bowel disease, Chron's disease
12/21/2010US7855192 A 2-azabicyclo(16.3.1)docosa-1(21),4,6,10,18-penntaen-9-ylcarbamate derivative; Heat shock protein 90 inhibitors; hyperproliferative disease, breast cancer, ovarian cancer, leukemia, colon cancer, lung cancer
12/21/2010US7855191 Agent having a destructive effect on malignant tumors and method for the production thereof
12/21/2010US7855190 Non-contraceptive benefits; e.g. reducing breakthrough bleeding by administering estrogen and progestin for more than 20 consecutive days, then administering an antidepressant with estrogen over specified time range(s)
12/21/2010US7855189 N-(2-nitrophenyl)phosphoric acid triamide obtained by reacting anilines or hydrochlorides with POCl3 OR PSCl3 for inhibiting urease-catalysed urea hydrolysis and combining with nitrification inhibitors pyrazole derivatives, a 1H-1,2,4-traizoles, dicyandiamide
12/21/2010US7855188 Quarternized amino glucosamine compound for exerting anticancer effect
12/21/2010US7855187 Alkylated semi-synthetic glycosaminoglycosan ethers, and methods of making and using thereof
12/21/2010US7855184 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes by endothelial cells and methods of treating ophthalmic and dermatological diseases
12/21/2010US7855183 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
12/21/2010US7855181 Dipeptides for prevention of muscle breakdown and microbial infection
12/21/2010US7855180 a silicon oxide porous body having gold particles as coverings for the pores and connecting members comprised of variable regions of an antibody, that bind to the gold particles, used for controlled release of drugs at a prescribed site
12/21/2010US7855174 Methods of treating vasodilatory shock
12/21/2010US7855075 Methods of controlling proliferation and differentiation of stem and progenitor cells
12/21/2010US7855056 Antibody against tumor specific antigen as target
12/21/2010US7854934 For treatment of cancer, preferably for prevention of recurrence of cancer, and for inducing antibodies in subject by administering glycopeptides
12/21/2010US7854933 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
12/21/2010US7854924 Administering sodium-binding polymer, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium
12/21/2010US7854922 Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose
12/21/2010US7854920 Bioavailability, nontoxic; 2-(3'-Iodo-4'-aminophenyl)-6-methoxybenzothiazole
12/21/2010US7854732 Fluid medication delivery device
12/21/2010US7854717 uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors
12/21/2010CA2659682C Prolyl hydroxylase inhibitors and methods of use
12/21/2010CA2618466C Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
12/21/2010CA2614633C A process for the preparation of suspensions of drug particles for inhalation delivery
12/21/2010CA2609494C Motilide compounds
12/21/2010CA2591246C Antimicrobial elastomer composition and method for making
12/21/2010CA2577937C Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
12/21/2010CA2569654C Benzimidazolone carboxylic acid derivatives
12/21/2010CA2564872C Iap bir domain binding compounds
12/21/2010CA2543201C ((ir, 3s)-3-isopropyl-3-{ [3-(trifluoromethyl)-7, 8-dihydro-1, 6-naphthyridin-6 (5h)-yl] carbonyl} cyclopentyl) [(3s, 4s)-3-methoxytetrahydro-2h-pyran-4-yl] amine succinate salt, composition thereof, and its use in the treatment of inflammatory diseases
12/21/2010CA2532067C N-methyle-substituted benzamidazoles
12/21/2010CA2520123C Drill device and method for forming microconduits
12/21/2010CA2503117C Substituted 4-alkoxyoxazol derivatives as ppar agonists
12/21/2010CA2494024C Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridyl-n-2-hydroxycarbonylethyl)-amide,the preparation thereof and their use as pharmaceutical compositions
12/21/2010CA2492718C Prodrugs of proton pump inhibitors
12/21/2010CA2483461C Isoquinoline derivatives
12/21/2010CA2483345C Imidazolinylmethyl aralkylsulfonamides
12/21/2010CA2477885C Pressurised metered dose inhalers containing solutions of beta-2 agonists
12/21/2010CA2470109C Substituted phenyl naphthalenes as estrogenic agents
12/21/2010CA2468374C Glp-1 derivatives
12/21/2010CA2464130C Mch antagonists for the treatment of obesity
12/21/2010CA2460956C Tetrapeptide derivative crystals
12/21/2010CA2453823C Dermal therapy using phosphate derivatives of electron transfer agents
12/21/2010CA2452596C Benzo-fused 5-membered heterocyclic compounds, their production and use
12/21/2010CA2450274C Benzoxazepine derivatives and their use as ampa receptor stimulators
12/21/2010CA2448896C Allylmercaptocaptopril compounds and uses thereof
12/21/2010CA2448425C Inhalation capsules
12/21/2010CA2444395C Use of nk-1 receptor antagonists against benign prostatic hyperplasia
12/21/2010CA2444130C Adenine derivatives
12/21/2010CA2441386C Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic
12/21/2010CA2434337C Combination of probiotics
12/21/2010CA2432137C Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
12/21/2010CA2426654C 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
1 ... 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 ... 7860